Olalekan O. Oluwole

Also affiliated with VA Tennessee Valley Healthcare System, Tennessee Oncology, Vanderbilt University Medical Center

MedicineImmunology and MicrobiologyEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.765Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States

Journal of Medical Economics(2023)10.1080/13696998.2023.2290832

Top 26%

0.765DataRank

Top 26%19 citations

Anik R. Patel, Sachin Vadgama, Nathaniel Smith, Rob Blissett, Chaoling Feng +4 more

Papers

Driven by 18 papers — median percentile 74. Top paper: “Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma”.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

New England Journal of Medicine(2017)10.1056/nejmoa1707447

N/A

1.3DataRank · unranked

5812 citations

Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson +41 more

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of Clinical Oncology(2020)10.1200/jco.19.02104

N/A

0.997DataRank · unranked

767 citations

Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin +23 more

An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States

Journal of Medical Economics(2023)10.1080/13696998.2023.2290832

Top 26%

0.765DataRank

Top 26%19 citations

Anik R. Patel, Sachin Vadgama, Nathaniel Smith, Rob Blissett, Chaoling Feng +4 more

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Clinical Hematology International(2021)10.2991/chi.k.210718.001

N/A

0DataRank · unranked

18 citations

Ameet Patel, Shi Huang, Yan Su, Kimberly B. Dahlman, Kelsey Tomasek +9 more

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Blood Advances(2022)10.1182/bloodadvances.2022008294

N/A

0DataRank · unranked

42 citations

Ana Alarcón Tomás, Jessica Flynn, Sean M. Devlin, Jamie Brower, Veronika Bachanová +10 more

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Blood Advances(2022)10.1182/bloodadvances.2022008937

N/A

0DataRank · unranked

20 citations

Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel‐Angel Perales +10 more

Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Transplantation and Cellular Therapy(2023)10.1016/j.jtct.2023.10.022

N/A

0DataRank · unranked

42 citations

Binod Dhakal, Tania Jain, Olalekan O. Oluwole, Gunjan L. Shah, Surbhi Sidana +3 more

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Blood Advances(2023)10.1182/bloodadvances.2023010302

N/A

0DataRank · unranked

35 citations

Jessica Flynn, Mithat Gönen, Sean M. Devlin, Allison Parascondola, Ana Alarcón Tomás +17 more

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Blood Advances(2023)10.1182/bloodadvances.2023011489

N/A

0DataRank · unranked

26 citations

Miriam T. Jacobs, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin +21 more

ZUMA‐24: A PHASE 2, OPEN‐LABEL STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA GIVEN OUTPATIENT WITH CORTICOSTEROIDS

Hematological Oncology(2023)10.1002/hon.3166_ot23

N/A

0DataRank · unranked

0 citations

Michael Tees, Ian W. Flinn, Tulio E. Rodriguez, J. Baird, Abhinav Deol +13 more

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of Clinical Oncology(2024)10.1200/jco.23.02786

N/A

0DataRank · unranked

74 citations

Jay Y. Spiegel, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin +27 more

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Blood Advances(2024)10.1182/bloodadvances.2023012549

N/A

0DataRank · unranked

33 citations

William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanová, Loretta J. Nastoupil +11 more

Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis

Blood Advances(2024)10.1182/bloodadvances.2024014164

N/A

0DataRank · unranked

24 citations

Connor B. Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T. Maziarz +12 more

ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.05.010

N/A

0DataRank · unranked

7 citations

Claire White, Magdi Elsallab, Stephanie Farnia, Ellen Fraint, Bambi Grilley +13 more

Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia

Blood Cancer Journal(2025)10.1038/s41408-025-01266-0

N/A

0DataRank · unranked

3 citations

Yuki Nishida, Kyung Hee Chang, Andrea Bedoy, Muharrem Müftüoğlu, Wencai Ma +13 more

Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma

Transplantation and Cellular Therapy(2025)10.1016/j.jtct.2025.09.015

N/A

0DataRank · unranked

3 citations

Olalekan O. Oluwole, Anik R. Patel, Markqayne D Ray, Yael Rodríguez‐Guadarrama, Nathaniel Smith +4 more

Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies

Circulation Research(2021)10.1161/circresaha.120.315894

N/A

0DataRank · unranked

129 citations

Olalekan O. Oluwole, Douglas B. Johnson, Nina Shah, Joe‐Elie Salem, Katy K. Tsai +2 more

Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8+ T cells during the primary immune response

Immunity(2021)10.1016/j.immuni.2021.02.018

N/A

0DataRank · unranked

127 citations

Kamir J. Hiam-Galvez, Diana M. Marquez, Iliana Tenvooren, Matthew Z. Madden, Diana C. Contreras +6 more

Olalekan O. Oluwole

Indexed papers

Top data-sharing exemplar

Papers